Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Investec Bank discloses equal purchase and sale of 128,034 Gamma Communications shares on June 22, 2026

Market News
23 Jun 2026
Na
View Source
Neutral
pluang ai news

Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed a public dealing on June 22, 2026, involving the purchase and sale of 128,034 ordinary shares of Gamma Communications. The transactions were conducted at prices ranging between 890 and 922 per share. There were no derivative or option dealings reported, and no special agreements influencing the trades. This disclosure is part of regulatory compliance under the Takeover Code, providing transparency on trading activities related to the company.

More News

Investec Bank discloses sale of 1,892 Treatt Group shares on June 22, 2026

Investec Bank discloses sale of 1,892 Treatt Group shares on June 22, 2026

Investec Bank plc, acting as advisor and joint broker to Treatt Group Plc, disclosed the sale of 1,892 ordinary shares of Treatt Group on June 22, 2026. The transaction involved shares sold at prices between 304 units each. This disclosure complies w...

Market News
Neutral
19 minutes ago
BlackRock increases stake in Deutsche Lufthansa to 4.04% as of June 17, 2026

BlackRock increases stake in Deutsche Lufthansa to 4.04% as of June 17, 2026

BlackRock, Inc. has raised its voting rights stake in Deutsche Lufthansa AG to 4.04% as of June 17, 2026, according to a regulatory filing. The increase reflects changes in direct and indirect voting rights through shares and financial instruments. T...

Market News
Neutral
24 minutes ago
DSV to release H1 2026 results on July 22 with webcast and Q&A session

DSV to release H1 2026 results on July 22 with webcast and Q&A session

DSV A/S will announce its interim financial results for the first half of 2026 on July 22, 2026. The company will host a webcast and conference call at 11:00 am CEST where CEO Jens H. Lund and CFO Michael Ebbe will present the report followed by a Q&...

Company Fundamentals
Neutral
44 minutes ago
EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses

EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses

The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...

Market News
Bullish
3 hours ago
argenx hosts webinar on advancing FcRn leadership in autoimmune myositis R&D

argenx hosts webinar on advancing FcRn leadership in autoimmune myositis R&D

argenx, a global immunology company, is hosting a webinar on June 23, 2026, focused on advancing research and development of FcRn blockers for autoimmune myositis. The event features argenx's management and scientific leaders alongside key external e...

Others
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App